Harneys advises China Biologic Products Holdings, Inc. on its US$4.76 billion take-private transaction

Harneys acted as Cayman Islands counsel to China Biologic Products Holdings, Inc. (China Biologic) on its take-private transaction valued at approximately US$4.76 billion.

Founded in 2002 and headquartered in Beijing, China Biologic is one of China’s leading plasma-based biopharmaceutical companies. The company’s core business focuses on research and manufacturing of plasma-based products used for the prevention and treatment of diseases and medical emergencies.

The Harneys team was led by Partners Julie Engwirda, Ian Mann, and Senior Associate James Granby, with support from Partners Paul Sephton, Raymond Ng, Lishi Fong, Paul Madden, and Senior Associate Anya Park. Onshore US counsel included Kirkland & Ellis LLP and Wilson Sonsini Goodrich & Rosati, with Fangda Partners providing PRC counsel.

Paul Sephton commented: “We are pleased to have assisted China Biologic on this successful transaction. This deal further highlights our team’s ability to provide unparalleled cross-border advice and service to our clients.”  

Harneys is a global offshore law firm with entrepreneurial thinking. Experts in British Virgin Islands, Cayman Islands, Cyprus, Luxembourg, Bermuda and Anguilla law, our lawyers are consistently recommended by leading independent legal directories. We advise an international client base including the world’s top law firms, financial institutions, investment funds and private individuals. Our network is one of the largest among offshore law firms, with locations in major financial centres in Europe, Asia, the Americas and the Caribbean, allowing us to provide services of the highest quality to clients in their own languages and time zones.